PegIFN-2b

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

36 competitors in CAR

#DrugCompanyPhaseTrials

1

Isopto Carpine

AAdvanz Pharma

Phase 3

32

Floxin

WWim Janssens

Phase 3

13

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

14

Pelacarsen

Novartis

Phase 3

15

L-Carnitine

IIperboreal Pharma Srl

Phase 3

16

Tegretol

Novartis

Phase 1

107

Tylenol

KKenvue Brands

Phase 2

18

Verquvo

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

19

Diamox

Teva

Phase 1

210

Trileptal

Novartis

Preclinical

4Show 11 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Hepatitis2 trials

Efficacy of Pegetron® Redipen™ Treatment and Treatment Compliance of Patients With Chronic Hepatitis C in Canada (P04423)

Completed·Merck & Co.··NCT00724893·2,430 enrolled

A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105)

Completed·Merck & Co.·Phase 4·NCT01756079·58 enrolled

Insulin resistance1 trial

A Study of Viral Response to Triple Therapy in Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy (MK-3034-113)

Withdrawn·Merck & Co.·Phase 4·NCT01770223

Hepatitis C1 trial

A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)

Completed·Merck & Co.·Phase 2·NCT00959699·99 enrolled

Combination Therapy1 trial

A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects

Completed·Bristol-Myers Squibb·Phase 3·NCT01718145·258 enrolled

Renal Impairment1 trial

Pharmacokinetics of Peginterferon Alfa-2b in Participants With Moderate and Severe Renal Impairment (P05655)

Completed·Merck & Co.·Phase 1·NCT01432535·25 enrolled

2 more indications

Renal Cell Carcinoma1 trial

Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)

Completed·Merck & Co.·Phase 1/2·NCT02089685·295 enrolled

CAR1 trial

Inactive HBsAg Carriers (IHCs) Treated With Pegylated Interferon α2b Based Intervention Therapy

Completed·HHenan Provincial People's Hospital·N/A·NCT05451420·33 enrolled

Details

Drug Info

Related News